Physician profile
Ashley Moon
NPI 1417301722
$1,084.99
in general payments reported to CMS, 2019-2025
11 companies · $398 in 2025
The $398 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $122 · 2024: $565 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,084.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $189.10 | 2024-2025 | |
| Glaxosmithkline, LLC. | $189.00 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $185.02 | 2024 | Lynparza |
| Eisai INC. | $163.05 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $89.03 | 2024-2025 | Keytruda, Lynparza |
| Caris Mpi, INC. | $87.04 | 2025 | Mi Cancer Seek |
| Myriad Genetic Laboratories, INC. | $86.70 | 2023-2024 | Myrisk, Precisetumor |
| Tempus Ai, INC | $29.09 | 2025 | Xt Cdx |
| Ethicon US, LLC | $26.88 | 2024 | Surgicel Nu-Knit, Vistaseal |
| Fennec Pharmaceuticals, INC. | $22.30 | 2025 | Fyarro |
| Integra Lifesciences Corporation | $17.78 | 2025 | Codman Certas, Codman Hakim, Cusa Clarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Moon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.